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Abstract: Little is known about the interplay between the autonomic nervous system and disease
activity in multiple sclerosis (MS). We examined the relationship between heart rate variability (HRV),
a reliable measure of vagal nerve function, and disease characteristics in a prospective MS cohort.
Standard deviation of each normal-to-normal inter-beat interval (SDNN) and root mean square of
successive differences (RMSSD), global indices of HRV, were measured in 114 MS patients, which
included four predefined subgroups, and 30 age and sex-matched healthy controls (HC). We assessed
group differences at baseline, HRV reproducibility at month 3, and used logistic regression modeling
to relate baseline HRV with relapse occurrence. No significant HRV differences were found between
MS and HC and between MS subgroups. In MS patients, both HRV indices correlated with age (r =
−0.278, p = 0.018 and r = −0.319, p < 0.001, respectively) and with month 3 assessments (r = 0.695 and r
= 0.760, p < 0.001). Higher SDNN and RMSSD at baseline were associated with self-reported relapses
at month 3 (OR = 1.053, 95% CI (1.013–1.095), p = 0.009 and OR = 1.065, 95% CI (1.016–1.117), p =
0.009), and SDNN at baseline with relapses at month 12 (OR = 1.034, 95% CI (1.009–1.059), p = 0.008;
ROC, AUC = 0.733, p = 0.002). There were no baseline HRV differences between MS and HC or
between subgroups. Post-hoc analysis showed an association with an increased relapse risk.
Keywords: multiple sclerosis; autonomic dysfunction; heart rate variability; relapse
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1. Introduction
Multiple sclerosis (MS) a complex, chronic disease of the central nervous system (CNS), is
known for its wide clinical, radiological, and pathological heterogeneity including a varying degree of
inflammation and neurodegeneration [1]. Most patients start with a relapsing-remitting course, which
may be followed by a secondary progressive phase. A minority of subjects present with an insidious
progression of disability from onset, or primary progressive [2].
Autonomic symptoms are prevalent in MS [3–5]. Based on the immunoregulatory functions of
the autonomic nervous system (ANS) [6], ANS dysfunction might play a role in the pathogenesis
and progression of MS. The vagal nerve, responsible for the main parasympathetic output, directly
communicates with the brain and can reduce peripheral inflammation in experimental conditions [7].
While some beneficial effects of vagal stimulation have been demonstrated in distinct inflammatory
diseases such as rheumatoid arthritis and inflammatory bowel disease [8,9], no data are available in MS.
The relation between ANS dysfunction and disease activity/severity in MS remains controversial [10].
This is probably related to the complexity of interactions among multiple variables, lack of prospective
studies, use of heterogeneous methods and the measured outcome parameters.
Heart rate variability (HRV), reflecting instantaneous parasympathetic modulation of cardiac
conduction, was shown to be a potent and reliable tool to examine ANS function in vivo with strong
correlations with vagal activity [11]. Several studies found lower HRV in MS patients than in healthy
controls (HC) [10,12,13], while others found more pronounced (para)sympathetic dysfunction in
progressive than in relapsing-remitting phenotypes [10,14,15]. Most studies did not account for the
effect of age on HRV [16,17].
Improving our understanding of HRV modulation in relation to the clinical and treatment
characteristics of MS, might be helpful for the identification of new prognostic biomarkers or for the
development of treatment approaches in MS. We therefore investigated the potential of HRV as an
indicator of heterogeneity with regard to the degree of inflammation, considering the vagal nerve’s
modulatory role in inflammation. We set up a prospective cohort study in predefined subgroups
of different MS phenotypes (including treated and untreated relapsing remitting (RRMS), primary
progressive (PPMS), and benign course MS) and age- and sex-matched healthy controls (HC). We
aimed to identify whether HRV measures are associated with MS (MS versus HC), with MS phenotype,
treatment status, or measures of disability and severity. We focused on the standard deviation of
each normal-to-normal inter-beat interval (SDNN) and the root mean square of successive differences
(RMSSD), measures of parasympathetic function and global HRV [18,19], as most relevant HRV
parameters [19,20], because they are simple to use and interpret, suitable for short-term recordings [19]
and have shown a predictive value in other diseases [21,22]. In addition, SDNN increases with
transcutaneous vagus nerve stimulation [20], proving that SDNN reflects parasympathetic activity [19].
High sensitive C-reactive protein (hsCRP) and neurofilament light (NFL) serum concentrations
were assessed at baseline, as they respectively reflect peripheral inflammation and neuronal damage,
respectively, and were previously used in MS studies [23,24]. In addition, hsCRP is related to SDNN
in healthy volunteers [25]. We assessed the stability of SDNN and RMSSD over three months and
investigated whether SDNN and RMSSD at baseline were associated with relapse occurrence during a
follow-up of 3 and 12 months.
2. Materials and Methods
MS patients from the National MS Center Melsbroek (NMSC) and the University Hospital
Brussel (UZB), diagnosed according to the 2010 revised McDonald criteria [26], were included. Onset
phenotype, disease course modifiers [27], and treatment status delineated predefined subgroups
(Table 1), including primary progressive (PP) and relapsing-remitting (RR) MS [28]. Based on the
difficulty to separate inflammation from neurodegeneration in the secondary progressive phase of
the disease, we did not include patients with secondary progressive MS in this study. We selected
one class of injectable immunomodulatory drugs in order to obtain a homogenous treatment group.
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Hence, IFN-beta was chosen, taking into consideration that patients could be treated with different
IFN preparations, resulting in a larger patient pool.
Table 1. Inclusion- and exclusion criteria. EDSS: expanded disease status scale.
Inclusion Criteria for Patients
Untreated active relapsing-remitting multiple
sclerosis (RRMS_U)
≥1 clinical relapse 2 years prior to screening or ≥1 active




≥3 months of stable treatment with interferon-bèta
EDSS < 7.0
Untreated benign multiple sclerosis (BMS) EDSS ≤ 3.0 at least 15 years after first symptoms [28]
Non-active primary-progressive multiple sclerosis
(PPMS)
No clinical relapse within 2 years prior to screening
EDSS < 7.0
Exclusion Criteria for Patients and Healthy Controls
Secondary progressive multiple sclerosis or other diseases of the central nervous system
Immunomodulatory drugs other than interferon-bèta at screening
Treatment with glatiramer acetate ≤3 months, fingolimod or natalizumab ≤6 months, or systemic corticosteroids
≤2 months prior to screening
HC were recruited to match the age- and gender distributions of the whole MS cohort. The
ethics committees of the UZB and the NMSC approved the study (B.U.N. 143201317985), conducted in
compliance with the Declaration of Helsinki (October 2013), the Belgian law on experimental research
in humans (5 July 2004) and the guidelines of Good Clinical Practice. All participants provided written
informed consent.
This study employed a prospective design and included intergroup comparisons at baseline and
assessment of self-reported relapses after three and twelve months. In line with previous studies [12,29],
we aimed to include 30 patients per subgroup. Demographics, clinical variables (Expanded Disability
Status Scale (EDSS) and the derived age-related MS severity score (ARMSS [30])), medication and
comorbidity were assessed at each visit.
A non-invasive two-lead ECG registration (eMotion HRV, Motion Ltd., Kuopio, Finland) in supine
position at rest, was performed at baseline (all MS and HC participants) and three months later (MS
and HC recruited in the NMSC) for 10 min (1000 Hz sampling frequency). Kubios HRV 2.1 software
(Department of Applied Physics, University of Eastern Finland, Kuopio, Finland) was used to select
the middle 5 min interval (2′30” to 7′30”), followed by ectopic interval detection (4th order filter) with
cubic spline interpolation and de-trending with Wavelet Packet in HRVAS software [18] as in [31]. The
batch processing function allowed a blinded analysis.
At baseline, each MS and HC participant provided a venous blood sample (10 mL EDTA tube),
which was immediately centrifuged at 3500 rpm during 15 min at 3–5 ◦C. The supernatant was
transferred to 1 mL cryotubes and stored in a −80 ◦C freezer. HsCRP and NFL concentrations were
determined in a blinded fashion with high sensitivity assays. HsCRP concentrations were measured
on a Vitros 4600 analyser (Ortho Clinical Diagnostics, Rochester, NY) using a immunoturbidimetric
latex immunoassay in high sensitive mode (CRP Vario, distributed by Abbott, Wiesbaden, Germany)
[Abott, Laboratories. C-reactive protein. 2008]. NFL concentrations were assessed on the Simoa® HD-1
Analyzer (NF-LIGHT®, Quanterix Corporation, Boston, MA, USA) according to the manufacturer’s
instructions [Quanterix, Corporation. Simoa NF-light advantage (SR-X) Kit. 2019]. The mean NFL
intra-assay coefficient of variation (CV) of the patient samples was 4.7%, while the inter-assay CV of an
internal quality control serum pool was 5.4%.
Variables with a non-Gaussian distribution were transformed to a normal distribution using the
LG10-transformation and rechecked for normality using the Skewness and Kurtosis tests. Demographic
and clinical intergroup differences at baseline were assessed with the independent samples t-test with
Levene’s test for equality of variances (2 groups), one-way ANOVA (>2 groups, Tukey HSD post-hoc
analysis) or Pearson chi-squared test (for categorical variables).
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An independent samples t-test and one-way ANOVA compared SDNN and RMSSD intergroup
differences at baseline between MS and HC, and between MS subgroups, respectively. Correlations
between continuous and categorical variables in MS samples were performed using the Pearson
correlation test and Pearson chi-squared test, respectively.
Reproducibility of HRV parameters at three months was assessed using the Pearson’s correlation
and Wilcoxon signed ranks tests. A binary logistic regression model included SDNN or RMSSD at
baseline as the independent variable, and relapse occurrence over three and twelve months (yes/no),
respectively, as the dependent variable. After checking for collinearity (r ≥ 0.25 [32]), non-collinear
variables (age, sex, and MS subgroup allocation) were forced into the multivariate model, while collinear
variables EDSS and NFL were added as an expression of age. This was done by first performing a linear
regression with EDSS or NFL as the dependent and age as the independent variable, then multiplying
the collinear variables by their respective regression coefficient. A receiver operating characteristic
(ROC) analysis was performed for SDNN at baseline and relapse occurrence over twelve months.
Statistical significance level was set at 0.05. Correction for multiple testing was performed using
the Bonferroni method (Padj). Analyses were performed using SPSS (IBM Corp. Released in 2016.
IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY).
3. Results
3.1. Study Population
Between February 2014 and October 2015, 114 MS patients and 30 HC were recruited (Figure 1).
Age, sex, comorbidities, and (non-immunomodulating) medication use did not significantly differ
between these groups. Demographics, clinical variables, self-reported relapses, systemic corticoids,
and treatment escalation during follow-up are summarized in Tables 2 and 3.
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Figure 1. Overview of the study population. BMS: benign multiple sclerosis; HRV: heart rate variability;
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Table 2. Demographics, clinical and biochemical data at baseline. Raw (P) and adjusted p-values (Padj)
are reported (Bonferroni). ARMSS: age-related multiple sclerosis severity; EDSS: expanded disease
status scale; CRP: C-reactive protein; Iqr: interquartile range; NA: not applicable; NFL: neurofilament
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Table 3. Prospective follow-up data. Only results for those with repeated HRV registration at month
three are shown. Adjusted p-values (Padj) are reported (Bonferroni). Frequencies are not cumulative.
IMD: immunomodulatory drug; Iqr: interquartile range; NA: not applicable; SDNN: standard deviation












(n = 18) Padj
HRV variables at month three




























Clinical variables at baseline–month three
Self-reported relapses NA 7 NA 4 2 1 0 NA
Systemic corticoid use NA 1 NA 1 0 0 0 NA
IMD escalation NA 7 NA 3 1 3 0 NA
Clinical variables at month three–month twelve
Self-reported relapses NA 9 NA 2 4 3 0 NA
Systemic corticoid use NA 0 NA 0 0 0 0 NA
IMD escalation NA 8 NA 5 3 0 0 NA
Comparative analysis confirmed that the MS and HC groups were comparable in terms of age and
sex distribution. The comparison between MS subgroups at baseline, however, revealed a significantly
higher age in PPMS than in RRMS_U (p = 0.003) and in RRMS_I (p = 0.004), as well as higher NFL levels
in PPMS than in BMS (p = 0.004) and RRMS_I (p = 0.002) in post-hoc analysis. EDSS was lowest in BMS
(p < 0.05) and highest in PPMS (p < 0.001) compared to other MS subgroups, while disease duration
was longer in BMS than in RRMS_U (p = 0.001) and PPMS (p = 0.039). ARMSS was significantly higher
in PPMS than in BMS (p < 0.001) and RRMS_U (p = 0.017).
3.2. Heart Rate Variability and Serum Samples
Three ECG recordings from HC at baseline were excluded because they contained >20% ectopic
beats. All ECG samples at month three were eligible (n = 97, NMSC samples only). Two blood samples
were lost during processing. Of the remaining 132 serum samples (97.8%), 35 samples (26.5%) had CRP
levels under the detection limit (<0.50 mg/L). These were given the value of 0.0 mg/L for statistical
purposes. All had valid NFL values (Table 2).
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3.3. Cross-Sectional Analysis
SDNN and RMSSD did not significantly differ between MS and HC (F = 1.029, Padj >0.1 and F
= 0.229, Padj > 0.1, respectively), nor between MS subgroups (F(3, 105) = 2.374, Padj > 0.1 and F(3,
105) = 2.319, Padj = 0.08, respectively). At visual inspection of the data, however, we did remark a
non-significantly higher SDNN and RMSSD at baseline in RRMS_U and BMS than in RRMS_I and
PPMS, which was mirrored in the month three SDNN results. SDNN and RMSDD were strongly
correlated at baseline (r = 0.884, Padj < 0.001). They were both inversely correlated with age (r =
−0.278, Padj = 0.018 and r = −0.319, Padj < 0.001, respectively), EDSS (r = −0.254, Padj = 0.042 and r
= −0.240, Padj = 0.01, respectively), and serum NFL (r = −0.251, Padj = 0.048 and r = −0.177, Padj =
0.04, respectively) in the whole MS population. A partial correlation test revealed that the correlation
between SDNN/RMSSD and serum NFL was explained by a collinear effect with age (partial r = −1.31,
p > 0.1 and partial r = −0.077, p > 0.1, respectively). There were no significant correlations between
HRV indices and sex, ARMSS, and serum CRP (Padj > 0.1).
3.4. Longitudinal Analysis
In MS patients, SDNN at baseline and three months correlated strongly over time at the group
level (r = 0.695, p <0.001), but had limited intra-individual reproducibility (Z = −2.343, p = 0.019).
Findings were similar for RMSSD at baseline and month 3 (r = 0.760, p <0.001 and Z = −2.211, p = 0.027).
The two SDNN outliers in Figure 2 reported a relapse within three (RRMS_U) or twelve months (BMS)
after baseline. These outliers are the same as for RMSSD. Exclusion of these outliers from analysis did
not change results.
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Figure 2. Scatterplot comparing SDNN values at baseline and after three months. The two datapoints
>100 ms on the Y-axis are considered outliers and are explained in the text. BMS: benign multiple sclerosis;
HRV: heart rate variability; PPMS: primary-progressive multiple sclerosis; RRMS_I: interferon-treated
relapsing-remitting multiple sclerosis; RRMS_U: untreated RRMS; SDNN: standard deviation of each
normal-to-normal inter-beat interval.
In MS patients, SDNN at baseline was significantly related to relapse occurrence at month 3 in
univariate (OR = 1.048, 95% CI (1.013–1.085), p = 0.007) and multivariate analysis (OR = 1.053, 95% CI
(1.013–1.095), p = 0.009). The same was true for relapse occurrence at month 12 in univariate (OR =
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1.031, 95% CI (1.009–1.054), p = 0.007) and multivariate analysis (OR = 1.034, 95% CI (1.009–1.059), p =
0.008). This is confirmed by an Independent samples t test wherein SDNN at baseline was compared
between MS patient that either had of did not have a relapse at month 12 (Independent samples t test,
F = 0.190, p = 0.005; Figure S1 in Supplementary material).
The logistic regression analysis was repeated with RMSSD at baseline and relapse occurrence
during the first 3 months (univariate OR = 1.051, 95% CI (1.014–1.089), p = 0.007; and multivariate
OR = 1.065, 95% CI (1.016–1.117), p = 0.009); and the total 12 months (univariate OR = 1.023, 95% CI
(1.000–1.047), p = 0.047); and multivariate OR = 1.028, 95% CI (0.999–1.057), p = 0.061).
Age, sex, MS subgroups allocation and age-corrected EDSS and NFL did not significantly
contribute to either multivariate model (p > 0.1).
The ROC curve for SDNN at baseline and the occurrence of relapses during twelve months is
shown in Figure 3 (AUC = 0.733, p = 0.002).J. Clin. Med. 2019, 8, x FOR PEER REVIEW 2 of 3 
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Figure 3. ROC curve illustrating sensitivity and specificity of SDNN at baseline on the occurrence
of self-reported relapses (AUC = 0.733, p = 0.002). Diagonal segments are produced by ties. AUC:
area under the curve; ROC: receiver operating characteristic; MS: multiple sclerosis; SDNN: standard
deviation of each normal-to-normal inter-beat interval.
4. Discussion
The present study did not find significant differences in SDNN or RMSSD between MS and HC,
nor between MS ubgroups. Some tudies i dicate lower SDN and RMSSD in MS (progressive
a d RRMS [10] or RRMS alone [12,13]) tha in HC, and others found higher SDNN in RRMS than
in progressive MS [10,15]. Differences in samples, methodology, and immunomodulatory treatment
make it difficult to compare th s results. Additionally, proper age-matching is nee ed to differentiate
betw en disease-related pathophysiology and ageing [16,17]. The observed correlation b tween
SDNN/RMSSD and NFL at bas in was ex lained by a collin ar effect with age. Rep ated SDNN
m asures showed a strong correlation at th group level, but were not individually reproducibl ,
illustrating the variable nature of HRV.
The positive relatio ship between baseline SDNN and RMSSD with relapses was surprising since
it contrasts with the hyp thesized health-protective effects of the vagal nerve in chronic diseases [22].
This has no been described reviously in MS. Furthermore, this relationship appears t be largely
driven by t eir association with relapses in the first three months, since th significant longitudinal
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effect of RMSSD is restricted to relapse occurrence during the first three months. Following the theory
that “T-cell immunity to self maintains the self” [33], we speculate that the vagus nerve may have
increased its anti-inflammatory activity [34] in response to raised sub-clinical CNS inflammation in
relapsing MS patients, which is supported by the observed anti-inflammatory effect of vagal stimulation
in mice studies on injury-induced inflammation [35]. Relapse occurrence could thus reflect a failing
or insufficient immune response. The lack of a correlation between SDNN/RMSSD and CRP at
baseline suggests no relationship with peripheral inflammation in this population. Finally, the positive
relationship between HRV and relapses observed here contradicts our observation that HRV was
inversely related to NFL.
While the relation between SDNN/RMSSD and relapses currently remains unexplained, we propose
to further investigate HRV as a marker of CNS inflammation in MS, in view of the anti-inflammatory
role of the vagus nerve [34].
We included patients with distinct MS disease courses [27] to maximize differences in presumed
inflammatory disease activity. The treated group was limited to interferon treatment. BMS was
included as a separate group, which has not been done in previous HRV studies in MS. A prospective
one-year follow-up allowed to examine the contribution of HRV to short-term disease evolution. Serum
biomarkers were collected to search for an underlying mechanism linking parasympathetic activity
and MS outcomes. Age distributions between MS and HC groups were matched and age was added to
the logistic regression model.
The study had a few limitations. Patient classification in MS has limitations. Strict inclusion
criteria for subgroups did not prevent that six patients started treatment shortly after inclusion. Most
probably, this decision was taken before recruitment. The HC group was small compared to the whole
MS sample. We used self-reported relapses, which were not necessarily confirmed by a physician.
Nonetheless, they have been used as a patient-reported outcome in other studies [36,37], with a
tendency towards underreporting [38]. We could not perform a cox regression analysis because the
exact timing of relapses was unknown. We did not control for diurnal variations in HRV. SDNN levels
in our HC group were lower and less variable than in Mahovic’s study (mean 30 ± 22.05 ms versus 135
± 24 ms [12]), which could be explained by the higher age and lower rate of ectopic beats in our HC
population [39]. While the intergroup analysis did not show any significant results, our study was
underpowered to detect significant SDNN/RMSSD differences between these MS subgroups. Therefore,
any MS intergroup difference in SDNN/RMSSD cannot be ruled out by these results alone. Lastly, not
all MS participants had MRI scans during the study and those that had, did not obtain them within a
predetermined time window. Therefore, we were not able to examine the relationship between HRV
and MRI results.
Nevertheless, this study included a relatively large MS sample and a prospective design, which
considered multiple confounders in the analysis. We recommend further exploration of the evolution
of HRV in a larger sample of RRMS patients before, during and after a physician-confirmed relapse, and
include longer prospective follow-up in RRMS and PPMS patients, including repeated measurements
of serum and CNS biomarkers for inflammation. This would improve our understanding of how
HRV interacts with acute and chronic CNS inflammation and possibly relates to the disease course.
Whether HRV and its relation to inflammation may have a prognostic effect on disease severity, as in
cancer [40,41], could be examined in MS as well.
5. Conclusions
HRV did not significantly differ between MS patients and healthy controls, nor between predefined
MS subgroups. However, a higher baseline SDNN and RMSSD was associated with relapse occurrence
during follow-up, most pronounced during the first three months. Our findings suggest a link between
HRV and ongoing disease activity in MS. We propose to investigate HRV and its relationship with
physician-confirmed relapses in long-term prospective studies to improve our understanding of the
link between vagal tone, neuro-inflammation, and the course of MS.
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